{"product_id":"therapeutic-proteins-isbn-9783527328499","title":"Therapeutic Proteins","description":"For this ready reference, the internationally renowned authority in the field, Roland Kontermann, has assembled a team of outstanding contributors from industry and academia to convey the worldwide knowledge on modifying therapeutic proteins in order to optimize their pharmacological potential. The result is a comprehensive work covering all approaches and aspects of the topic in one handy volume, making this indispensable reading for companies and research institutions working on the development of biopharmaceuticals. GENERAL INFORMATION\u003cbr\u003e Half-life modulating strategies - an introduction (Roland Kontermann)\u003cbr\u003e \u003cbr\u003e Pharmacokinetics and half-life protein of therapeutics (Bernd Meibohm)\u003cbr\u003e \u003cbr\u003e HALF-LIFE EXTENSION THROUGH CHEMICAL AND POSTTRANSLATIONAL MODIFICATIONS\u003cbr\u003e Half-life extension through PEGylation (Simona Jevsevar and Menci Kunstelj)\u003cbr\u003e \u003cbr\u003e Half-life extension of therapeutic proteins via genetic fusion to recombinant PEG mimetics\u003cbr\u003e (Uli Binder and Arne Skerra)\u003cbr\u003e \u003cbr\u003e Half-life extension through O-glyosylation (Fuad Fares)\u003cbr\u003e \u003cbr\u003e Polysialic acid and polysialylation to modulate antibody pharmacokinetics (Antony Constantinou, Chen Chen and Mahendra P. Deonarain)\u003cbr\u003e \u003cbr\u003e Half-life extension through HESylation (Thomas Hey, Helmut Knoller and Peter Vorstheim)\u003cbr\u003e \u003cbr\u003e HALF-LIFE MODULATION INVOLVING RECYCLING BY THE NEONATAL FC RECEPTOR\u003cbr\u003e The biology of FcRn (Jonghan Kim)\u003cbr\u003e \u003cbr\u003e Half-life extension by fusion to the Fc region (Jalal A. Jazayeri and Graeme J Carroll)\u003cbr\u003e \u003cbr\u003e Monomeric Fc fusion Technology: an approach to create long lasting clotting factors (Jennifer A. Dumont, Xiaomei Jei, Robert T. Peters, Alvin Luk, Glenn F. Pierce and Alan J. Bitonti)\u003cbr\u003e \u003cbr\u003e The diverse roles of FcRn: implications for antibody engineering (Sally Ward and Raimund J. Ober)\u003cbr\u003e \u003cbr\u003e Half-life extension by fusion to albumin (Hubert J. Metzner, Thomas Weimer and Stefan Schulte)\u003cbr\u003e \u003cbr\u003e AlbudAb(TM) technology platform: versatile albumin binding domains for the development of therapeutics with tunable half-lives (Christopher Herring and Oliver Schon)\u003cbr\u003e \u003cbr\u003e Half-life extension by binding to albumin through an albumin-binding domain (Fredrik Frejd)\u003cbr\u003e \u003cbr\u003e Half-life extension by binding to albumin through small molecules (Sabrina Trussel, Joerg Scheuermann and Dario Neri)\u003cbr\u003e \u003cbr\u003e HALF-LIFE EXTENSION WITH PHARMACEUTICAL FORMULATIONS\u003cbr\u003e Half-life extension with pharmaceutical formulations: liposomes (Astrid Hartung and Gerd Bendas)\u003cbr\u003e \u003cbr\u003e Half-life extension with pharmaceutical formulations: nanoparticles (Katharina Landfester)\u003cbr\u003e \"The majority of future protein therapeutics will be modified in one way or another using techniques and concepts described in this monograph. Therefore it can be safely stated that this is an extremely relevant contribution, which should be on hand for all those who think about or work on protein therapeutics.\" (\u003ci\u003eBiotechnology Journal\u003c\/i\u003e, Nov 2012) Roland Kontermann obtained his PhD in Molecular Biology from the University of Heidelberg. After working as a postdoc in the laboratory of Sir Gregory Winter at the MRC Centre for Protein Engineering, Cambridge, UK, he was a group leader at the Institute of Molecular Biology and Tumor Biology of the University of Marburg, and subsequently Head of Research at vectron therapeutics AG. Since 2004 he is Professor of Biomedical Engineering at the Institute of Cell Biology and Immunology of the University of Stuttgart. Current research focuses on the development of recombinant bispecific and bifunctional antibody molecules, including half-life extension strategies, and targeted nanoparticulate carrier systems for tumor therapy. He has over 60 scientific publications and co-editor (together with Stefan Dubel) of the Antibody Engineering Lab Manual.","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47990381904101,"sku":"NP9783527328499","price":145.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9783527328499.jpg?v=1761787599","url":"https:\/\/k12savings.com\/es\/products\/therapeutic-proteins-isbn-9783527328499","provider":"K12savings","version":"1.0","type":"link"}